share_log

Reported Earlier, Novartis Secures Third FDA Approval For Oral Fabhalta In Rare Kidney Disease C3G

Benzinga ·  Mar 21 06:15
  • Phase III study showed sustained proteinuria reduction at one year with favorable safety1
  • Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G1-3
  • C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney failure2-4
  • Novartis continues to advance multiple kidney disease treatments with high unmet need, compounding capabilities and strengthening unique leadership presence
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 319

Recommended

Write a comment